With the aim of boosting is leadership team, clinical-stage biotech Zura Bio (Nasdaq: ZURA) today announced the appointments of Robert Lisicki as president and chief operating officer, and Kiran Nistala as executive vice president development and chief medical officer, to the executive leadership team.
Mr Lisicki will be responsible for developing and driving the business plan and strategic initiatives as Zura Bio builds a leading immunology company. Dr Nistala will be responsible for the development strategy of prioritized pipeline products.
Zura noted that both Mr Lisicki and Dr Nistala have successfully worked on or led in the development of multiple drugs within the auto-immune therapeutic area. These executives position Zura Bio to deliver on the promise of their innovative medicines for patients in need of better clinical outcomes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze